The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Companies   »  Analyzing the Price-to-Earnings Ratio of Ampio Pha...

Analyzing the Price-to-Earnings Ratio of Ampio Pharmaceuticals Inc. (AMPE)

The 36-month beta value for AMPE is also noteworthy at 1.76. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”

The average price estimated by analysts for AMPE is $600.00, The public float for AMPE is 0.69M, and at present, short sellers hold a 3.09% of that float. The average trading volume of AMPE on September 19, 2023 was 28.80K shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


AMPE) stock’s latest price update

Ampio Pharmaceuticals Inc. (AMEX: AMPE)’s stock price has soared by 9.60 in relation to previous closing price of 4.27. Nevertheless, the company has seen a loss of -8.24% in its stock price over the last five trading days. InvestorPlace reported 2023-06-22 that The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.

AMPE’s Market Performance

AMPE’s stock has fallen by -8.24% in the past week, with a monthly rise of 14.09% and a quarterly drop of -8.24%. The volatility ratio for the week is 17.10% while the volatility levels for the last 30 days are 12.17% for Ampio Pharmaceuticals Inc. The simple moving average for the past 20 days is 15.78% for AMPE’s stock, with a -7.54% simple moving average for the past 200 days.

AMPE Trading at 6.86% from the 50-Day Moving Average

After a stumble in the market that brought AMPE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.24% of loss for the given period.

Volatility was left at 12.17%, however, over the last 30 days, the volatility rate increased by 17.10%, as shares surge +11.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.40% lower at present.

During the last 5 trading sessions, AMPE fell by -8.24%, which changed the moving average for the period of 200-days by -41.50% in comparison to the 20-day moving average, which settled at $4.07. In addition, Ampio Pharmaceuticals Inc. saw 3.91% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at AMPE starting from BUCHI J KEVIN, who purchase 21,858 shares at the price of $0.29 back on Jun 09. After this action, BUCHI J KEVIN now owns 146,858 shares of Ampio Pharmaceuticals Inc., valued at $6,284 using the latest closing price.

BUCHI J KEVIN, the Director of Ampio Pharmaceuticals Inc., purchase 25,000 shares at $0.30 during a trade that took place back on Jun 08, which means that BUCHI J KEVIN is holding 125,000 shares at $7,400 based on the most recent closing price.

Stock Fundamentals for AMPE

The total capital return value is set at -100.37, while invested capital returns managed to touch -81.76. Equity return is now at value -139.50, with -106.90 for asset returns.

Based on Ampio Pharmaceuticals Inc. (AMPE), the company’s capital structure generated 5.21 points at debt to equity in total, while total debt to capital is 4.95. Total debt to assets is 4.52, with long-term debt to equity ratio resting at 2.32. Finally, the long-term debt to capital ratio is 2.21.

The liquidity ratio also appears to be rather interesting for investors as it stands at 11.18.


In summary, Ampio Pharmaceuticals Inc. (AMPE) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.